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Research
Increased cardiovascular mortality and mor­
bidity have been reported in association with 
increases in daily ambient levels of particulate 
matter (PM) in epidemiologic studies (Analitis 
et al. 2006; Le Tertre et al. 2002; Samet et al. 
2000). However, it is not known which con­
stituents of particles are responsible for the 
effects associated with particle mass. The 
source of particles defines their composition. 
Recent epidemiologic studies suggest that par­
ticles from combustion sources are especially 
harmful (Laden et al. 2000; Lanki et al. 2006). 
Transition metals and organic carbon com­
pounds were shown to be toxic in a toxicologic 
study (Pagan et al. 2003). These can be found 
in abundance in combustion particles.
The relative importance of different path­
ways from particle exposure to effects on the 
cardiovascular system is not clear, but expo­
sure to particles has been associated both with 
increased systemic inflammation and changes 
in autonomic nervous control of the heart 
(Brook et al. 2004). The latter is most often 
measured indirectly as heart rate variability 
(HRV) (Task Force 1996). A decreased overall 
HRV has proven to be a strong independent 
predictor of cardiac mortality in subjects with 
existing cardiovascular disease (La Rovere et al. 
1998; Nolan et al. 1998). Several studies have 
shown decreased indices of HRV on days with 
increased outdoor levels of respirable particles 
[aerodynamic diameter < 10 µm (PM10)] (Liao 
et al. 2004; Lipsett et al. 2006) and fine par­
ticles [< 2.5 µm (PM2.5)] (Holguín et al. 2003; 
Schwartz et al. 2005).
In the Exposure and Risk Assessment for 
Fine and Ultrafine Particles in Ambient Air 
(ULTRA) study, levels of outdoor air pol­
lution were monitored for 6–8 months in 
1998–1999 in three European cities. At the 
same time, panels of patients with coronary 
heart disease were followed up with measure­
ments of HRV. We previously reported that 
the levels of ultrafine particles (PM < 0.1 µm) 
were associated with changes in the balance 
between sympathetic and vagal nervous input 
to the heart (Timonen et al. 2006). However, 
PM2.5 in particular showed different associa­
tions with HRV in the different study centers. 
In Helsinki, Finland, elevated concentrations 
of PM2.5 were associated with decreased high 
frequency (HF) and increased low frequency 
(LF)/HF ratio, whereas the opposite was true 
in Erfurt, Germany. No such associations were 
observed in Amsterdam, the Netherlands.
In the present article, we evaluate whether 
exposure misclassification, effect modifica­
tion by medication, or variable particle com­
position could explain these inconsistencies. 
Personal and indoor PM2.5 were measured 
in Amsterdam and Helsinki to obtain more 
accurate estimates of exposure. Possible effect 
modification by beta­blocker (β­adrenergic 
antagonist) medication or obesity was evalu­
ated in light of the limited number of earlier 
studies (Chen et al. 2007; Park et al. 2005; 
Wheeler et al. 2006). For comparison, we also 
tested other medication possibly modifying 
the effect of particulate air pollution on HRV.
Finally, we linked source­specific PM2.5 with 
HRV to evaluate the importance of particle 
composition for cardiovascular effects of PM. 
Methods
Heart rate variability was measured at biweekly 
clinic visits in panels of elderly subjects with 
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Ba c k g r o u n d : It has been hypothesized that ambient particulate air pollution is able to modify the 
autonomic nervous control of the heart, measured as heart rate variability (HRV). Previously we 
reported heterogeneous associations between particulate matter with aerodynamic diameter < 2.5 µm 
(PM2.5) and HRV across three study centers. 
oB j e c t i v e : We evaluated whether exposure misclassification, effect modification by medication, or 
differences in particle composition could explain the inconsistencies. 
Me t h o d s : Subjects with coronary heart disease visited clinics biweekly in Amsterdam, the 
Netherlands; Erfurt, Germany; and Helsinki, Finland for 6–8 months. The standard deviation 
(SD) of NN intervals on an electrocardiogram (ECG; SDNN) and high frequency (HF) power of 
HRV was measured with ambulatory ECG during paced breathing. Outdoor levels of PM2.5 were 
measured at a central site. In Amsterdam and Helsinki, indoor and personal PM2.5 were measured 
during the 24 hr preceding the clinic visit. PM2.5 was apportioned between sources using principal 
component analyses. We analyzed associations of indoor/personal PM2.5, elements of PM2.5, and 
source-specific PM2.5 with HRV using linear regression. 
re s u l t s : Indoor and personal PM2.5 were not associated with HRV. Increased outdoor PM2.5 was 
associated with decreased SDNN and HF at lags of 2 and 3 days only among persons not using 
beta-blocker medication. Traffic-related PM2.5 was associated with decreased SDNN, and long-
range transported PM2.5 with decreased SDNN and HF, most strongly among persons not using 
beta blockers. Indicators for PM2.5 from traffic and long-range transport were also associated with 
decreased HRV. 
co n c l u s i o n s : Our results suggest that differences in the composition of particles, beta-blocker use, 
and obesity of study subjects may explain some inconsistencies among previous studies on HRV.
ke y w o r d s : absorbance, air pollution, cardiovascular health, elements of PM2.5, heart rate variabil-
ity, medication, PM2.5, source-specific particulate matter. Environ Health Perspect 117:105–111 
(2009).  doi:10.1289/ehp.11062 available via http://dx.doi.org/ [Online 25 August 2008]de Hartog et al.
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coronary heart disease in Amsterdam, Erfurt, 
and Helsinki in 1998–1999. In Amsterdam, 
37 panelists were followed for 8 months, and 
in Erfurt and Helsinki, 47 panelists were fol­
lowed for 6 months. The visits of every subject 
were always scheduled for the same weekday 
and for the same time. The medication of 
the subjects was not changed for the clinic 
visits. Outdoor levels of PM2.5 were measured 
concurrently with the visits at one central site 
in each city. In Helsinki and Amsterdam, 
indoor and personal measurements of PM2.5 
were also performed during the 24 hr preced­
ing the clinic visit. All measurements in the 
study were performed according to standard 
operating procedures (Brunekreef et al. 2005; 
Pekkanen et al. 2000).
The main inclusion criteria for the study 
were a self­report of a physician­diagnosed 
coronary heart disease, being a nonsmoker, 
and age ≥ 50 years. Ethical committees in 
each study center approved the study proto­
col. A written informed consent was obtained 
from all subjects.
At the clinic visits, HRV was recorded 
with an ambulatory electrocardiogram 
(ECG) recorder (Medilog MR 63 recorder; 
Oxford Instruments, Abington, UK) using a 
standardized protocol (Timonen et al. 2006). 
Breathing frequency strongly affects HRV, 
and for that reason, HRV recorded during 
a 5­min period of paced breathing in supine 
position (frequency 0.2 Hz; 2.5­sec inhala­
tion and 2.5­sec exhalation) has been used 
for the analyses. Two­channel ambulatory 
ECG recordings were performed with analog 
ambulatory ECG recorders (Medilog MR 63 
recorder; Oxford Instruments) using standard 
electrode position for leads V1 and V5. The 
recordings were analyzed with ambulatory 
ECG analysis software (Exel Medilog II V7.5 
system; Oxford Instruments). The record­
ings were digitized with a sampling rate of 
128 Hz. The software used an interpolation 
algorithm to refine the R wave fiducial point 
and to improve the resolution in R­peak 
detection. Details of the analyses have been 
published previously (Tarkiainen et al. 2005; 
Timonen et al. 2006).
We were mainly interested in explaining 
the heterogeneous results in the main end 
points [the SD of NN intervals (SDNN), 
HF, and LF/HF ratio] of a previous ULTRA 
paper (Timonen et al. 2006). Therefore, we 
used two common indices of HRV in the 
present analyses: SDNN, which is a time­
domain measure of overall HRV, and HF 
power (0.15–0.4 Hz) of HRV, which is a 
frequency domain measure believed to reflect 
mainly the vagal (parasympathetic) part of 
the autonomic nervous input to the heart. 
HF is highly correlated with r­MSSD, a 
commonly used time­domain variable (Task 
Force 1996). The LF/HF ratio was left out 
of the paper, because the interpretation and 
physiological basis are more controversial.
Information on physician­administrated 
daily medication was collected at baseline 
visit. Medication categories tested for effect 
modification were beta­blockers, calcium 
(Ca2+) channel blockers, statins, angiotensin­
converting enzyme (ACE) inhibitors, angi­
otensin receptor blockers, and acetylsalicylic 
acid (ASA). Antiarrhythmic medication was 
not included in the analyses because of lim­
ited use among study participants (7%).
Harvard impactors (BGI, Inc., Waltham, 
MA, USA) were used to collect filter sam­
ples of outdoor PM2.5; GK2.05 cyclones and 
battery­operated AFC400S pumps (BGI, 
Inc.) were used for the collection of personal 
PM2.5 samples. The filters were weighted to 
determine mass of PM2.5, and reflectance 
was measured with a reflectometer (Model 
43, Diffusion Systems Ltd., London, UK). 
The reflectance was transformed into absorb­
ance [absorption coefficient (ABS)], which 
is an indicator for elemental carbon. Finally, 
elemental composition of the samples was 
determined using energy­dispersive X­ray 
fluorescence spectrometry. All methods have 
been described in detail in previous papers 
(Brunekreef et al. 2005; de Hartog et al. 
2005; Janssen et al. 2000, 2005).
We used principal­component analysis 
and multivariate linear regression to apportion 
PM2.5 mass to different sources (Vallius et al. 
2005), thereby obtaining estimates of daily 
source­specific PM2.5 concentrations. Besides 
components of PM2.5 (elemental concentra­
tions and absorbance), daily data on ultrafine 
(diameter < 0.1 µm) and accumulation mode 
particles (0.1–1.0 µm), nitrogen dioxide, and 
sulfur dioxide were used to identify sources. 
 We identified four to six main source 
categories in each city: local traffic (with 
contribution from other local combustion 
sources), long­range transported (secondary) 
air pollution, industry, crustal, oil combus­
tion, and salt (Vallius et al. 2005).
We analyzed data using the SAS statistical 
package and mixed models (PROC MIXED) 
(SAS Institute Inc., Cary, NC, USA) taking 
into account repeated observations and assum­
ing constant correlation between observations 
within a subject. A basic model was first built 
without including particulate air pollution 
in the model. Criteria for building the basic 
model were Akaike’s information criterion and 
covariate­response plots. The same basic mod­
els as in the previous paper have been used 
(Timonen et al. 2006). Lag 0 was defined as 
the 24­hr period from noon of the day of the 
clinic visit to noon of the previous day, lag 1 
was the previous 24­hr period, and so on. In 
Amsterdam, the model included linear terms 
for time trend, temperature (lag 2), relative 
humidity (lag 3), and barometric pressure. In 
Erfurt, the model included linear terms for time 
trend, relative humidity (lag 3), and barometric 
pressure (lag 2). Temperature (lag 3) was mod­
eled with linear, squared, and cubic terms. The 
basic model for Helsinki included linear terms 
for time trend, relative humidity (lag 1), and 
barometric pressure (lag 1). Temperature (lag 
3) was modeled with linear and squared terms. 
In all cities, the model included weekday as a 
categorical variable. Results were insensitive to 
alternative model specifications.
For comparison of the effects of outdoor, 
indoor, and personal PM2.5 on HRV, only the 
days with all three types of measurements were 
included in the analyses. We analzed asso­
ciations of source­specific PM2.5 with HRV 
using multipollutant models that included at 
the same time all identified sources and the 
unidentified PM2.5 fraction. Multipollutant 
models were not used for elements of PM2.5 
because of high intercorrelations. We ana­
lyzed data only for the elements that are either 
indicators for the PM2.5 sources or that have 
been found harmful in toxicologic studies. The 
Table 1. Characteristics of three study panels.
Characteristic  Amsterdam (n = 33)a  Erfurt (n = 44)a  Helsinki (n = 45)a
Sex/female [no. (%)]  11 (34)  4 (9)  21 (47)
Mean age (range)  70.9 (54–83)  64.3 (40–78)  68.2 (54–83)
Obeseb [no. (%)]  7 (19)  7 (15)  16 (34)
Past myocardial infarction [no. (%)]  22 (69)  30 (68)  27 (60)
Angina pectoris [no. (%)]  21 (66)  24 (55)  29 (64)
CABG or PTCA conducted [no. (%)]  17 (53)  31 (70)  23 (51)
Daily beta-blocker medication [no. (%)]  13 (39)  34 (77)  31 (69)
Ca2+ channel blockers [no. (%)]  11 (30)  18 (38)  13 (28)
Statins [no. (%)]  12 (32)  20 (43)  21 (45)
ACE inhibitors and angiotensin receptor blockers [no. (%)]  12 (32)  25 (53)  10 (21)
ASA [no. (%)]  22 (59)  36 (77)  36 (77)
Meanc SDNN (SD), msec         
  Beta-blocker users  46.7 (17.8)  29.9 (8.8)  35.3 (10.7)
  Nonusers  40.0 (11.9)  41.2 (12.1)  38.8 (11.7)
Meanc HF (SD), msec2        
  Beta-blocker users  414 (289)  280 (237)  600 (376)
  Nonusers  504 (307)  547 (396)  629 (409)
Abbreviations: CABG, coronary artery bypass graft; PTCA, percutaneous transluminal coronary angioplasty. 
aNumber of patients available for analyses. bObese = body mass index ≥ 30 kg/m2. cAverage of individual means and SDs. Effect modifiers of PM2.5 associated with HRV
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indicators were chosen based on the elemen­
tal profiles of sources (Vallius et al. 2005): 
absorbance for local traffic; sulfur for long­
range transported particles; vanadium for oil 
combustion (not used for Erfurt because oil 
source was not identified there, and > 50% of 
concentrations were below detection limit); Ca 
for soil particles; and chloride for salt particles 
(not in Erfurt). Elements considered because 
of potential toxicity were the transition metals 
copper, iron, and zinc. 
HF was log­transformed for the analy­
ses, and the effect of particulate air pollution 
on the end point was estimated as percent 
change: [e(β × IQR)–1] × 100%, where β is the 
estimated regression coefficient and IQR is 
the interquartile range. Effect estimates for 
the elements are presented for increases that 
are close to study mean interquartile ranges 
(IQRs)—the differences between the 25th 
and 75th percentiles of the exposure distribu­
tions. Pooled effect estimates were calculated 
as a weighted average of the center­specific 
estimates using the inverse of center­specific 
variances as weights. The heterogeneity of 
effect estimates between centers was tested 
with a chi­square test (Normand 1999).
Effect of extreme source­specific PM2.5 
values on the results was evaluated by exclud­
ing at each lag the concentrations that were 
more than three times the IQR. 
Results
There were 424 clinical visits in Amsterdam, 
491 in Erfurt, and 519 in Helsinki. Although 
special care was given to attachment of the 
electrodes, some ECG recordings were unsuc­
cessful. There were 366 successful recordings 
(from 33 patients) in Amsterdam, 432 (44) 
in Erfurt, and 468 (45) in Helsinki.
In Helsinki, the proportion of males and 
females was almost equal, but in Amsterdam 
the panel contained mostly males and in 
Erfurt almost exclusively males (Table 1). 
Obesity was common in Helsinki, where one­
third of the study subjects were obese (17 
persons). There were clearly fewer obese per­
sons in Amsterdam and Erfurt (7 in both). 
The most commonly used medication was 
ASA. About two­thirds of the study sub­
jects in Erfurt and Helsinki had daily beta­
blocker medication, whereas only about 
one­third of the subjects were on medica­
tion in Amsterdam. Except for SDNN in 
Amsterdam, HRV indices were lower among 
beta­blocker users than among nonusers.
Outdoor levels of PM2.5 were lower in 
Helsinki than in Amsterdam and Erfurt 
(Table 2). In Helsinki, about half of PM2.5 was 
of secondary origin, that is, could be consid­
ered long­range transported; in Amsterdam 
and Erfurt, this was about one­third. Industrial 
sources of PM2.5 were not identified in Helsinki 
(Vallius et al. 2005). Oil combustion and salt as 
sources of PM2.5 were not identified in Erfurt, 
and the indicator elements for these sources 
have not been included.
PM2.5 (total) correlated most strongly with 
long­range transported PM2.5, and the cor­
relation with S, the indicator element for this 
source, was even higher (Table 3). Transition 
metals Zn, Fe, and Cu correlated highly with 
absorbance, with the correlation highest for 
Cu in Amsterdam (r = 0.83) and lowest for Fe 
in Helsinki (r = 0.49) (data not shown).
The medians of individual averages (num­
ber of measurements) of outdoor, indoor, 
and personal PM2.5 in Amsterdam were 21.0 
(417), 14.9 (411), and 15.3 (338) µg/m3, 
respectively. The respective PM2.5 levels in 
Helsinki were 12.0 (478), 10.2 (503), and 
10.0 (336) µg/m3 (Janssen et al. 2000).
Outdoor, indoor, and personal PM2.5 
were not associated with SDNN at lag 0 
(Figure 1). Indoor and personal PM2.5 meas­
urements were not available at lags 1, 2, or 3. 
There was a suggestive positive association of 
outdoor and personal PM2.5 with HF. 
Among study subjects not on daily beta­
blocker medication, increased concentrations 
of PM2.5 were associated with decreased SDNN 
and HF, especially at longer lags (Figure 2). 
For this group the city­specific estimates were 
homogeneous. There was a positive association 
at single (1­day) lag between PM2.5 and HF 
among subjects who were on medication. 
There was no consistent modification 
of the effects of PM sources by medication 
other than beta­blockers (results not shown). 
Those not using ACE inhibitors or angio­
tensin receptor blockers had more clearly 
decreased HF in association with long­range 
transported PM than all subjects [at lag 2: 
–1.25; 95% confidence interval (CI), –2.09 
to –0.41; at lag 3: –1.1; 95% CI, –2.04 to 
Table 2. Daily outdoor levels of PM2.5, its components, and temperature at central measurement sites in three cities.
  Amsterdam (n = 223)  Erfurt (n = 156)  Helsinki (n = 164)
  p25  p50  p75  p95  p25  p50  p75  p95  p25  p50  p75  p95
PM2.5 (µg/m3)  10.4  16.7  23.9  47.0  10.8  16.3  26.7  62.3  8.3  10.6  15.9  25.8
Source-specific PM2.5 (µg/m3)          
  Local traffic   3.5  6.1  9.3  20.4  4.1  7.0  10.0  18.4  1.7  2.6  3.4  6.5
  Long-range transported   0.3  5.1  11.6  21.8  3.1  5.4  9.8  31.9  2.2  5.5  9.8  15.9
  Oil combustion  0.9  1.6  3.1  5.9  NA  NA  NA  NA  0.6  1.3  2.3  4.2
  Industry   –2.6  –0.5  3.0  9.2  –3.6  –1.6  2.2  24.7  NA  NA  NA  NA
  Crustal   0.7  1.4  2.1  3.6  1.8  2.7  4.8  13.8  0.0  0.4  1.1  2.2
  Salt  0.1  0.2  0.8  1.8  NA  NA  NA  NA  0.3  0.8  1.2  2.4
  Absorbance (m–1 × 10–5)  0.9  1.5  2.2  3.4  1.3  2.0  3.4  5.1  1.4  1.89  2.47  3.56
Elements (ng/m3)              
  S   936  1,340  2,240  3,650  600  862  1,530  3,740  839  1,380  2,080  3,400
  V   2.5  4.1  7.8  14.7  NA  NA  NA  NA  3.2  6.69  9.8  16.4
  Zn   8.7  18.2  33.9  65.2  22.6  40.2  75.1  199  11.3  16.8  25.1  47.3
  Ca  26.9  37.1  51.8  76.9  34.6  47.0  72.2  193  22.7  32.3  47.3  87.0
  Cl  33.8  116  432  990  NA  NA  NA  NA  8.1  36.4  102  386
  Fe  47.1  70.7  107  175  38.6  59.9  112  248  39.3  66.7  100  165
  Cu  1.4  2.5  4.7  9.0  0.6  2.5  4.9  10.4  0.6  1.6  2.8  5.1
Temperature (°C)  4.4  7.9  12.3  16.9  –0.1  3.9  6.7  11.2  –5.0  –0.6  2.5  8.8
Abbreviations: NA, not available; p25, 25th percentile; p50, 50th percentile (median); p75, 75th percentile; p95, 95th percentile.
Table 3. Correlation (Spearman’s correlation coefficients.) of total PM2.5 with source-specific PM2.5 and elements at central sites in three cities.
  Source-specific PM2.5  Elements of PM2.5
PM2.5  Traffic  LRT  Oil  Industry  Crustal  Salt  ABS  S  V  Zn  Ca  Cl  Fe  Cu
Amsterdam (n = 223)  0.50  0.62  0.18  0.27  –0.15  0.04  0.73  0.84  0.27  0.81  0.04  0.14  0.68  0.63
Erfurt (n = 156)  0.32  0.57  NA  0.41  0.19  NA  0.81  0.85  NA  0.82  0.51  0.63  0.81  0.70
Helsinki (n = 164)  0.26  0.82  0.35  NA  –0.01  0.19  0.70  0.85  0.59  0.77  0.17  –0.03  0.38  0.42
Abbreviations: NA, not available; LRT, long-range transported. de Hartog et al.
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–0.26], but same kind of modifying effect 
was not observed for other sources or SDNN. 
On the other hand, those not using statins 
had decreased HF in association with PM2.5 
at a 3­day lag (–6.45; 95% CI, –11.63 to 
–0.96), but no modifying effect of statins was 
observed for source­specific PM2.5 or SDNN. 
Obesity was not associated with beta­
blocker use: 60.0% of obese and 60.4% of non­
obese persons used beta­blockers. However, 
obesity itself seemed to modify the effects of 
PM2.5. At a 3­day lag, PM2.5 was associated with 
SDNN (–1.99; 95% CI, –3.69 to –0.30) and 
HF (–12.50; 95% CI, –20.1 to –4.24) among 
obese persons, whereas such an effect was not 
observed among all subjects. Effects of long­
range transported PM2.5 were similarly modi­
fied by obesity (results not shown), obviously 
because of substantial correlation between PM2.5 
and long­range transported PM2.5. However, no 
such effect modification was observed for PM2.5 
from traffic or other sources of PM2.5.
Increases in PM2.5 originating from local 
traffic were consistently associated with 
decreased SDNN, somewhat more strongly 
among study subjects not using beta­block­
ers than in the whole study panel (Table 4). 
Long­range transported PM2.5 was associated 
with decreased SDNN and HF at lags 2 and 3 
among persons not having daily beta­blocker 
medication. Among all subjects, there was 
hetero  geneity in the effect estimate for long­
range transported PM at a 2­day lag for HF 
because of negative estimates in Amsterdam 
(–0.91; 95% CI, –2.02 to 0.22) and Helsinki 
(–1.92; 95% CI, –3.26 to –0.57) and a posi­
tive estimate in Erfurt (0.25; 95% CI, –0.81 
to 1.31). There was evidence of the effect of 
PM2.5 from oil combustion only for SDNN 
among nonmedicated subjects. Crustal PM2.5 
was associated with increased HF irrespec­
tive of medication use at lag 2. Associations 
between 5­day average (lags 0–4) particulate 
air pollution and HRV were weaker than for 
individual lags (data not shown).
The fraction of PM2.5 that could not be 
linked to any particular source category was 
positively associated at 0­day lag with SDNN 
(estimate 0.18; 95% CI, 0.00 to 0.35) and HF 
(1.53; CI, 0.48 to 2.59) among all study sub­
jects, but the association was not evident among 
subjects not using beta­blockers. The positive 
association between unidentified PM2.5 frac­
tion and SDNN disappeared when extreme 
source­specific PM2.5 concentrations were 
excluded from the analyses. Overall, exclusions 
of extreme values did not change the interpre­
tation of the results. After exclusion, the city­
  specific estimates were no longer heterogeneous 
for the association of long­range transported 
PM2.5 with HF at lag 2 among all study centers.
Among persons not having daily beta­
blocker medication, increases in absorbance 
(local traffic) and S (long­range transport) 
were consistently associated with decreased 
SDNN and HF (Table 5). The associations 
between V (oil combustion) and HRV were 
less consistent, and for the other source indi­
cators there was no evidence of an effect. 
Table 4. Pooled effect estimates in three study panels [β (95% CIs)]a for the associations of source-specific 
PM2.5 with HRV in multipollutant models.b
  SDNN (msec)  HF (%)
  All subjects  Subjects without beta-blockers  All subjects  Subjects without beta-blockers
Local traffic       
  Lag 0  –0.05 (–0.26 to 0.15)  0.11 (–0.23 to 0.44)  0.11 (–1.05 to 1.28)  0.31 (–1.65 to 2.30)
  Lag 1  –0.12 (–0.36 to 0.12)  –0.27 (–0.59 to 0.05)  0.43 (–0.91 to 1.79)  –0.21 (–2.16 to 1.77)
  Lag 2  –0.28 (–0.57 to 0.01)  –0.45 (–0.90 to 0.01)  –0.13 (–1.74 to 1.50)  –0.67 (–3.34 to 2.07)
  Lag 3  –0.20 (–0.45 to 0.06)  –0.35 (–0.69 to 0.00)  –0.64 (–2.03 to 0.78)  –1.43 (–3.40 to 0.58)
Long-range transport      
  Lag 0  0.00 (–0.10 to 0.09)  –0.03 (–0.19 to 0.14)  0.12 (–0.43 to 0.67)  –0.18c (–1.13 to 0.77)
  Lag 1  –0.04 (–0.14 to 0.06)  0.00 (–0.15 to 0.16)  0.19 (–0.38 to 0.77)  0.06 (–0.86 to 0.99)
  Lag 2  –0.05 (–0.17 to 0.07)  –0.11 (–0.30 to 0.07)  –0.69c (–1.35 to –0.02)  –1.06 (–2.14 to 0.03)
  Lag 3  0.00 (–0.13 to 0.12)  –0.20 (–0.39 to –0.01)  –0.54 (–1.23 to 0.15)  –1.98 (–3.07 to –0.88)
Oil combustiond      
  Lag 0  –0.02 (–0.74 to 0.70)  –0.46 (–1.34 to 0.41)  3.20 (–0.48 to 7.03)  1.43 (–3.83 to 6.97)
  Lag 1  –0.29 (–1.04 to 0.45)  –1.08 (–2.09 to –0.06)  1.05 (–2.70 to 4.94)  –3.04 (–8.80 to 3.08)
  Lag 2  0.36 (–0.42 to 1.13)  0.22 (–0.89 to 1.33)  1.50 (–2.36 to 5.51)  0.10 (–6.34 to 6.98)
  Lag 3  0.00 (–0.77 to 0.77)  –0.43 (–1.27 to 0.42)  0.49 (–3.25 to 4.38)  –0.42 (–5.32 to 4.73)
Industryd      
  Lag 0  –0.07 (–0.23 to 0.09)  –0.17 (–0.43 to 0.10)  0.13 (–0.80 to 1.07)  0.08 (–1.44 to 1.62)
  Lag 1  0.03 (–0.12 to 0.19)  –0.14 (–0.44 to 0.16)  0.62 (–0.34 to 1.59)  –0.08 (–1.79 to 1.65)
  Lag 2  0.02 (–0.12 to 0.16)  –0.08 (–0.34 to 0.18)  0.05 (–0.82 to 0.94)  –1.03 (–2.53 to 0.49)
  Lag 3  –0.04 (–0.17 to 0.09)  0.12 (–0.19 to 0.42)  –0.05 (–0.87 to 0.77)  0.68 (–0.98 to 2.37)
Crustal       
  Lag 0  –0.02 (–0.36 to 0.31)  –0.05 (–0.84 to 0.75)  0.01 (–2.07 to 2.15)  0.80 (–3.47 to 5.26)
  Lag 1  0.11 (–0.35 to 0.56)  0.07 (–0.97 to 1.11)  1.57 (–1.28 to 4.50)  1.93 (–3.86 to 8.06)
  Lag 2  0.18 (–0.37 to 0.73)  0.35 (–0.82 to 1.52)  4.72 (1.16 to 8.41)  5.67 (–1.11 to 12.91)
  Lag 3  0.11 (–0.43 to 0.66)  0.20 (–1.05 to 1.45)  0.93 (–2.43 to 4.41)  2.68 (–4.02 to 9.84)
Saltd      
  Lag 0  1.07 (–0.66 to 2.80)  –0.03 (–2.61 to 2.55)  5.20 (–3.83 to 15.08)  4.33 (–10.46 to 21.56)
  Lag 1  –0.19 (–1.92 to 1.55)  –0.64 (–3.29 to 2.00)  –1.43 (–9.86 to 7.78)  4.33 (–10.68 to 21.87)
  Lag 2  –0.33 (–2.13 to 1.47)  –0.44 (–2.88 to 2.00)  –1.06 (–9.69 to 8.38)  –6.55 (–18.85 to 7.62)
  Lag 3  1.47 (–0.28 to 3.22)  2.17 (–0.07 to 4.41)  6.70 (–2.30 to 16.52)  2.74 (–9.65 to 16.83)
aβ, effect estimate for an increase of 1 µg/m–3 in source-specific PM2.5. bThe number of observations in the analyses was 
1,195 for SDNN and 1,183 for HF. cPooled effect estimates have heterogeneous underlying center-specific effect estimates 
(significance test < 0.05). dOil combustion source and salt source of PM2.5 were not identified in Erfurt; industrial source of 
PM2.5 was not identified in Helsinki; estimates of only two cities pooled.
Figure 1. Pooled effect estimates (95% CIs) for two 
study panels (Amsterdam and Helsinki) for the asso-
ciation outdoor, indoor, and personal PM2.5 at 0-day 
lag with HRV (SDNN and HF). Effect estimates are 
calculated for an increase of 10 µg/m3 for PM2.5 and 
1 m–1 × 10–5 for absorbance.


































Figure 2. Pooled effect estimates (95% CIs) for 
three study panels for the association of outdoor 
PM2.5 with HRV (SDNN and HF) stratified by beta-
blocker use. Effect estimates are calculated for an 
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However, for the transition metals (Cu, Fe, 
and Zn) included because of potential toxic­
ity, there was some evidence of negative asso­
ciations with HRV at longer lags.
Discussion
In this panel study conducted among persons 
with coronary heart disease in three European 
cities, personal, indoor, or outdoor PM2.5 
measured during the 24 hr preceding clinic 
visit (lag 0) were not associated with HRV. 
However, at 2­ and 3­day lags, we observed 
that daily increases in outdoor levels of PM2.5 
were associated with decreased HRV, but only 
among persons not on beta­blocker medica­
tion. When we linked source­specific PM2.5 to 
HRV, we observed increases in traffic­related 
PM2.5 to be associated with decreased SDNN, 
especially among persons who were not on 
beta­blocker medication. Daily increases in 
the long­range transported PM2.5 were associ­
ated both with decreased HF and SDNN, 
more strongly or exclusively among nonmedi­
cated persons. In separate analyses, indicator 
elements for these two sources, absorbance 
and S, were also negatively associated with 
HRV among persons not on medication. 
There was also evidence for a negative associa­
tion of transition metals with HRV.
We reported previously that outdoor lev­
els of PM2.5 were not consistently associated 
with HRV in the three study panels (Timonen 
et al. 2006). However, people spend most of 
their time indoors, and persons with com­
promised health, like the panel members in 
our study, even more so (Brunekreef 2005). 
Consequently, outdoor levels of particulate 
air pollution measured at a central site may 
not be perfect proxies for variation in personal 
PM exposure. However, we did not find per­
sonal or indoor PM2.5 to be associated with 
decreased HRV. Unfortunately, we had only 
personal and indoor measurements in the 24 
hr preceding the clinic visit, and PM2.5 mass 
and composition during that time period were 
not associated with HRV. Our observation 
thus indicates only that the lack of association 
at 0­day lag for outdoor PM2.5 was not due to 
exposure misclassification. In some studies, 
the effects of PM on HRV have been observed 
even within hours of exposure (Devlin et al. 
2003; Gold et al. 2000). However, the use of 
daily averages to measure PM2.5 exposure in 
our study prevented us from detecting possible 
immediate effects of PM. 
Beta­blockers have been shown to enhance 
HRV in patients with coronary heart disease 
(Niemela et al. 1994; Sandrone et al. 1994). 
Consistent with this, we observed increased 
outdoor levels of PM2.5 to be associated with 
decreased SDNN and HF (at 2­ and 3­day 
lags) only among persons not using beta­block­
ers. Effect modification by medication use 
thus seems to explain the lack of associations 
between PM2.5 and HRV in our previous anal­
ysis (Timonen et al. 2006). There was little 
evidence of effect modification by any other 
medication group in the present study.
The interpretation of earlier studies evalu­
ating the importance of beta­blocker use for 
the effects of ambient particles on HRV is 
somewhat difficult because of the differences 
in disease status between users and nonusers of 
beta­blockers. In a study by Park et al. (2005) 
conducted among veteran men, beta­blocker 
users were all hypertensive, whereas only half of 
the nonusers had hypertension. No clear effect 
of PM2.5 (adjusted for ozone) on SDNN or 
HF was observed in either medication group. 
However, the low­frequency component of 
HRV decreased in association with PM2.5 only 
among persons not using beta­blockers. In a 
study by Wheeler and coworkers (2006), all but 
one of the beta­blocker users were myocardial 
infarction survivors, whereas most nonusers had 
chronic obstructive pulmonary disease. Effect 
modification by beta­blocker use was reported 
only for SDNN, which decreased in association 
with PM2.5 among users and increased among 
nonusers. In the present study, all patients had 
coronary heart disease, and our results suggest 
that the use of beta­blockers modifies the effect 
of PM on HRV even in this more homogene­
ous patient group.
Medication use is obviously never inde­
pendent of health status. Consequently, the 
suggestive increase in HF in association with 
PM2.5 among beta­blocker users in our study 
may indicate either that the use of medication 
changes the direction of the association, or that 
those with less severe heart disease differ in their 
response to particulate air pollution. Obesity 
has been suggested to modify the effects of PM 
on HRV (Chen et al. 2007), which was con­
firmed by our results. PM2.5 seemed to be more 
strongly associated with HRV among obese 
persons. In our study, obesity was not associ­
ated with beta­blocker use.
Table 5. Pooled effect estimates [β (95% CIs)]a in three study panels for the associations of elements of 
PM2.5 with HRV among study subjects in single-pollutant models.
  SDNN (msec)  HF (%)
  All subjects  Subjects without beta-blockers  All subjects  Subjects without beta-blockers
ABS     
  Lag 0  –0.54 (–1.39 to 0.31)  –0.64 (–2.25 to 0.97)  0.45 (–4.48 to 5.64)  –2.54 (–11.15 to 6.91)
  Lag 1  –0.52 (–1.46 to 0.41)  –1.59 (–3.11 to –0.06)  2.91 (–2.54 to 8.67)  –4.94 (–13.04 to 3.91)
  Lag 2  –0.78 (–1.72 to 0.16)  –1.36 (–2.99 to 0.27)  –1.42 (–6.76 to 4.22)  –7.13 (–15.51 to 2.08)
  Lag 3  –0.31 (–1.23 to 0.62)  –1.44 (–3.15 to 0.27)  –2.57 (–7.75 to 2.90)  –7.83 (–16.27 to 1.45)
S     
  Lag 0  –0.25 (–1.06 to 0.55)  –0.71 (–1.98 to 0.56)  0.74 (–3.76 to 5.46)  –2.70 (–9.71 to 4.84)
  Lag 1  –0.51 (–1.36 to 0.33)  –0.76 (–1.99 to 0.47)  0.25b (–4.42 to 5.14)  –3.61 (–10.36 to 3.64)
  Lag 2  –0.43 (–1.39 to 0.52)  –1.44 (–2.84 to –0.04)  –4.78b (–9.69 to 0.40)  –10.56 (–17.63 to –2.87)
  Lag 3  0.10 (–0.88 to 1.08)  –1.54 (–3.02 to –0.06)  –4.02 (–9.01 to 1.25)  –13.05 (–20.18 to –5.29)
Vc      
  Lag 0  –0.12 (–1.14 to 0.91)  –0.46 (–1.85 to 0.93)  4.58 (–0.89 to 10.36)  3.68 (–4.72 to 12.82)
  Lag 1  –0.66 (–1.73 to 0.41)  –1.97 (–3.56 to –0.39)  0.73 (–4.74 to 6.53)  –6.24 (–14.71 to 3.07)
  Lag 2  0.40 (–0.66 to 1.46)  –0.16b (–1.72 to 1.39)  1.40 (–4.02 to 7.13)  –4.58 (–12.97 to 4.61)
  Lag 3  0.04 (–0.99 to 1.07)  –0.43 (–1.78 to 0.91)  –1.92 (–7.00 to 3.45)  –2.09 (–9.64 to 6.09)
Zn       
  Lag 0  –0.19 (–0.79 to 0.41)  –0.69 (–1.83 to 0.46)  1.68 (–1.97 to 5.46)  0.40 (–5.91 to 7.13)
  Lag 1  0.12 (–0.55 to 0.79)  –0.78 (–2.11 to 0.54)  3.85 (–0.26 to 8.13)  0.13 (–6.92 to 7.72)
  Lag 2  0.06 (–0.58 to 0.70)  –0.92 (–2.20 to 0.37)  2.28 (–1.71 to 6.43)  –3.78 (–10.41 to 3.35)
  Lag 3  –0.13 (–0.72 to 0.46)  –0.28 (–1.53 to 0.96)  –1.43 (–4.95 to 2.22)  –6.41 (–12.60 to 0.22)
Ca     
  Lag 0  –0.23 (–0.85 to 0.38)  –0.72 (–2.17 to 0.73)  –0.77 (–4.50 to 3.10)  –0.37 (–8.12 to 8.04)
  Lag 1  0.27 (–0.58 to 1.11)  –0.47 (–2.16 to 1,21)  3.39 (–1.80 to 8.86)  2.10 (–7.18 to 12.31)
  Lag 2  0.62 (–0.36 to 1.60)  0.35 (–1.47 to 2.18)  7.89 (1.70 to 14.46)  5.60 (–4.98 to 17.35)
  Lag 3  0.03 (–0.93 to 1.00)  0.01 (–2.03 to 2.05)  0.61 (–5.01 to 6.56)  –0.01 (–10.58 to 11.81)
Clc     
  Lag 0  0.25 (–0.25 to 0.76)  0.07 (–0.48 to 0.61)  2.36 (–0.15 to 4.94)  2.34 (–1.00 to 5.79)
  Lag 1  0,14 (–0.39 to 0.67)  0.00 (–0.63 to 0.64)  1.13 (–1.48 to 3.81)  1.46 (–2.39 to 5.46)
  Lag 2  0.38 (–0.12 to 0.88)  0.32 (–0.22 to 0.85)  1.40 (–1.06 to 3.94)  1.71 (–1.56 to 5.08)
  Lag 3  0.31 (–0.17 to 0.80)  0.37 (–0.13 to 0.87)  1.21 (–1.15 to 3.61)  0.81 (–2.21 to 3.91)
Fe       
  Lag 0  –0.32 (–1.25 to 0.61)  –0.32 (–1.94 to 1.29)  0.72 (–4.49 to 6.22)  –0.12 (–9.19 to 9.86)
  Lag 1  0.15 (–1.00 to 1.30)  –1.09 (–2.85 to 0.67)  6.69 (0.11 to 13.69)  0.13 (–9.70 to 11.04)
  Lag 2  –0.44 (–1.72 to 0.84)  –1.51 (–3.58 to 0.56)  1.50 (–5.52 to 9.04)  –3.31 (–14.26 to 9.05)
  Lag 3  –0.44 (–1.67 to 0.79)  –1.77 (–3.86 to 0.32)  –3.45 (–9.90 to 3.46)  –9.93 (–20.26 to 1.72)
Cu     
  Lag 0  –0.18 (–0.73 to 0.36)  –0.29 (–1.26 to 0.68)  1.56 (–1.65 to 4.87)  –0.97 (–6.40 to 4.77)
  Lag 1  –0.08 (–0.74 to 0.57)  –0.20 (–1.19 to 0.78)  3.00 (–0.85 to 7.00)  2.34 (–3.49 to 8.52)
  Lag 2  –0.43 (–1.10 to 0.24)  –1.55 (–2.71 to –0.39)  1.71 (–2.30 to 5.88)  –4.16 (–10.53 to 2.67)
  Lag 3  0.12 (–0.56 to 0.80)  –0.54 (–1.59 to 0.51)  –1.97 (–5.76 to 1.98)  –4.41 (–9.91 to 1.43)
aβ, effect estimate, calculated for an increase of 1 m–1 × 10–5 in absorbance, 1 µg/m3 in S, 4 ng/m3 in V, 30 ng/m3 in Ca and 
Zn, 100 ng/m3 in Cl, 70 ng/m3 in Fe, and 2 ng/m3 in Cu. bPooled effect estimates have heterogeneous underlying center-
specific effect estimates (significance test < 0.05). cV and Cl were not used in Erfurt; estimates of only two cities pooled.de Hartog et al.
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Clinical studies have related decreased 
HRV in cardiac patients with increased risk 
of mortality over relatively long periods of 
follow­up (Task Force 1996). The extent to 
which short­term decreases in HRV measures 
predict short­term mortality is not known. 
However, vagal withdrawal is observed a 
few minutes before transient ischemic events 
(Kochiadakis et al. 2000; Kop et al. 2001), 
suggesting that short­term changes in HRV 
are not harmless. In a large study among 
elderly subjects (de Bruyne et al. 1999), 
increased HRV has been even more strongly 
associated with decreased survival than 
decreased HRV. Taking this into account, 
our study cannot be straightforwardly inter­
preted as showing that beta­blocker use is 
protective against the effects of particulate air 
pollution on cardiovascular health, because 
there was a suggestive increase in HF in asso­
ciation with PM2.5 among medicated persons.
There was some indication of the effects 
of traffic­ related PM2.5 on SDNN, and long­
range transported PM2.5 on HF and SDNN 
even before taking medication into account, 
but after considering beta­blocker use, the 
associations became stronger. Some earlier 
studies have evaluated the effects of traffic­
related particles on HRV without conducting 
source apportionment. Absorbance, consid­
ered as an indicator for traffic­originating par­
ticles, has been more strongly associated with 
HRV among elderly subjects than PM2.5 
(Schwartz et al. 2005). In­vehicle PM2.5 was 
more strongly associated with HRV in healthy 
young men than were ambient or roadside 
PM2.5 (Riediker et al. 2004a). In­vehicle PM2.5 
was further apportioned among different 
sources (Riediker et al. 2004b), and strongest 
associations were observed between PM2.5 from 
brake wear and engine emissions and HRV. 
Schwartz et al. (2005) evaluated indirectly 
the effects of secondary particles on HRV and 
found no effect. They regressed PM2.5 against 
black carbon concentrations and interpreted 
residuals to represent the fraction of second­
ary particles that varied independently from 
primary combustion particles. It is possible 
that the effects of long­range transported PM2.5 
on HRV in our study are related to primary 
combustion particles generated, for example, 
by regional traffic. In our study, the effect esti­
mates (for SDNN) per microgram of particle 
mass were clearly higher for local traffic­related 
PM2.5 than for long­range transported parti­
cles. However, there was also some evidence 
of the effects of PM2.5 from oil combustion on 
SDNN. The results are consistent with our pre­
vious study, where PM2.5 from traffic and other 
local combustion was most strongly associated 
with the occurrence of ST segment depressions 
in Helsinki, but long­range transported particles 
and possibly oil combustion were also contrib­
uting to the effects of PM2.5 (Lanki et al. 2006).
In the last part of our analyses, we evalu­
ated the associations of HRV with elements 
of PM2.5 and absorbance, a proxy for ele­
mental carbon content of particles. In these 
analyses, decreased HRV was associated 
with absorbance and S, which were consid­
ered markers for local traffic and long­range 
transported PM2.5, respectively. The finding 
thus confirmed the analyses conducted using 
source­specific PM2.5. However, long­range 
transported PM2.5 also contains traffic­origi­
nating PM and elemental carbon. There was 
also evidence of the negative associations of 
V (oil combustion), Zn (e.g., industry), Fe, 
and Cu with HRV, but the associations were 
mostly nonsignificant. Transition metals are 
typically associated with combustion proc­
esses, so it was not a surprise that absorbance 
was highly correlated with Zn, Fe, and Cu. 
It has been suggested that organic carbon 
compounds and transition metals attached 
to elemental carbon core (approximated by 
absorbance) are responsible for the effects of 
PM on health (Obot et al. 2002).
Toxicologic studies have often observed 
cellular defenses to be even more responsive to 
the coarse particle fraction (PM10–PM2.5) than 
to finer­size fractions (Hetland et al. 2004; 
Soukup and Becker 2001). The ambient lev­
els of coarse particles are typically dominated 
by crustal material, whereas PM2.5 levels are 
more influenced by combustion emissions. 
In a recent study (Lipsett et al. 2006), coarse 
particles were associated with decreased HRV, 
whereas PM2.5 was not. Interestingly, we found 
increases in HF in association with increased 
outdoor levels of crustal PM2.5. On the other 
hand, the chosen indicator element for crustal 
PM2.5—Ca—was not associated with HF.
Our study has both strengths and weak­
nesses. The study had rather stringent inclu­
sion criteria for the study subjects to obtain a 
homogeneous cardiac panel presumably vul­
nerable for the effects of air pollution (von 
Klot et al. 2005). The three study centers used 
common standard operating procedures and 
standardized equipment, and Holter record­
ings were analyzed in a single lab. HRV was 
recorded during a paced breathing period to 
avoid influence of breathing patterns on the 
results. However, because we measured out­
door levels of source­specific PM2.5 instead 
of actual exposure, exposure misclassification 
may have biased the results. We previously 
reported considerable longitudinal correlations 
between outdoor and personal PM2.5, absorb­
ance (traffic), and S (long­range transport), 
but correlations were lower for Ca (soil), Cl 
(salt), and Cu (Janssen et al. 2005). Finally, 
our source­specific PM2.5 levels are not always 
products of homogeneous sources but rather 
of broader source categories.
In conclusion, we found PM2.5 originating 
from local traffic and other local combustion 
and also long­range transported PM2.5 to be 
associated with decreased indices of HRV. The 
effects were stronger among persons not using 
beta­blocker medication and among obese 
persons. Differences in the composition of 
particles and medication use or disease severity 
of study subjects may explain some inconsist­
encies between previous studies on HRV.
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